MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1212/wnl.0000000000011269

Медицинская библиотека · Neurology · 2020

Pathologic Features of Anti-Mi-2 Dermatomyositis.

Tanboon Jantima, Inoue Michio, Hirakawa Shinya, Tachimori Hisateru, Hayashi Shinichiro, Noguchi Satoru, Suzuki Shigeaki, Okiyama Naoko, Fujimoto Manabu, Nishino Ichizo

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To identify the characteristic pathologic features of dermatomyositis (DM) associated with anti-Mi-2 autoantibodies (anti-Mi-2 DM).

METHODS

We reviewed 188 muscle biopsies from patients (1) pathologically diagnosed with DM through the sarcoplasmic expression for the myxovirus-resistant protein A and (2) serologically positive for 1 of 5 DM-specific autoantibodies (DMSAs) (anti-Mi-2, n = 30; other DMSAs, n = 152) or negative for all 5 DMSAs (n = 6). We then compared the histopathologic and immunohistochemical features of patients with anti-Mi-2 DM to those with non-Mi-2 DM and patients with anti-synthetase syndrome (ASS) (n = 212) using the t test, Fisher exact test, and a logistic regression model.

RESULTS

Patients with anti-Mi-2 DM showed significantly higher severity scores in muscle fiber and inflammatory domains than non-Mi-2 DM patients. The presence of perifascicular necrosis, increased perimysial alkaline phosphatase activity, and sarcolemmal membrane attack complex deposition was more frequent in patients with anti-Mi-2 DM (p < 0.01). After Bonferroni correction, there were no significant differences in the percentages of the features mentioned above between the patients with anti-Mi-2 DM and those with ASS (p > 0.01).

CONCLUSION

Perifascicular necrosis and perimysial pathology, features previously reported in ASS, are common in patients with anti-Mi-2 DM. Our findings not only assist in differentiating anti-Mi-2 DM from other DM subtypes but also suggest the possibility of an overlapping mechanism between anti-Mi-2 DM and ASS.

CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that the muscle biopsies of DM patients with anti-Mi-2 autoantibodies are more likely to demonstrate higher severity scores in muscle fiber and inflammatory domains.

Для цитирования: Tanboon Jantima, Inoue Michio, Hirakawa Shinya, Tachimori Hisateru, Hayashi Shinichiro, Noguchi Satoru, Suzuki Shigeaki, Okiyama Naoko, Fujimoto Manabu, Nishino Ichizo. Pathologic Features of Anti-Mi-2 Dermatomyositis.. Neurology. 2020. DOI: 10.1212/wnl.0000000000011269.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.